DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-187828 |   Service

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Duchenne Muscular Dystrophy Drug Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET

7.1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Bristol-Myers Squibb

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Santhera Pharmaceuticals

16.3 Akashi Therapeutics

16.4 Acceleron Pharma

16.5 PTC Therapeutics

16.6 Catabasis Pharmaceuticals

16.7 Summit Therapeutics

16.8 Nobelpharma

16.9 BioMarin Pharmaceutical

16.10 Eli Lilly

16.11 Nippon Shinyaku

16.12 Janssen Pharmaceuticals

16.13 Sarepta Therapeutics

16.14 Lexicon Pharmaceuticals

16.15 Marathon Pharmaceuticals

16.16 Pfizer

16.17 Capricor Therapeutics

16.18 Asklepios BioPharmaceuticals

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
Steroid Therapy
Exon Skipping
Mutation Suppression

By Application
Translarna
Emflaza
EXONDYS 51

Companies

Bristol-Myers Squibb
Santhera Pharmaceuticals
Akashi Therapeutics
Acceleron Pharma
PTC Therapeutics
Catabasis Pharmaceuticals
Summit Therapeutics
Nobelpharma
BioMarin Pharmaceutical
Eli Lilly
Nippon Shinyaku
Janssen Pharmaceuticals
Sarepta Therapeutics
Lexicon Pharmaceuticals
Marathon Pharmaceuticals
Pfizer
Capricor Therapeutics
Asklepios BioPharmaceuticals

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.